SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Chi-Med's NDA for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

Hutchison China MediTech Limited ("Chi-Med") (NASDAQ: HCM) today announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration ("NMPA") has granted Priority Review status to the New Drug Application ("NDA") for surufat

Benzinga · 12/20/2019 10:19

Hutchison China MediTech Limited ("Chi-Med") (NASDAQ: HCM) today announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration ("NMPA") has granted Priority Review status to the New Drug Application ("NDA") for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine tumors ("NET").

"Surufatinib is our second drug to be granted priority review by the NMPA," says Christian Hogg, Chief Executive Officer of Chi-Med. "We are working closely with the NMPA as they review our NDA for the treatment of non-pancreatic NET. Surufatinib being granted priority review is a positive step forward in potentially bringing this innovative drug to patients, who currently have very limited treatment options."

In November 2019, the NDA for surufatinib for the treatment of non-pancreatic NET was accepted for review by the NMPA, and the U.S. Food and Drug Administration granted Orphan Drug designation to surufatinib for the treatment of pancreatic NET.